Clinical trial
A Randomised, Single-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Ascending Administration of Otelixizumab in Subjects With Type 1 Diabetes Mellitus
NCT00946257 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Single-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Ascending Administration of Otelixizumab in Subjects With Type 1 Diabetes Mellitus
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 8, 2009
- Completion date
- June 25, 2013
- Enrollment
- 33 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.